There are now three GLP-1RA drugs approved in multiple countries [see Table 1] for chronic weight management, all of which are administered as injections: Wegovy (active substance semaglutide) and Saxenda (active substance liraglutide) from Novo Nordisk, and Mounjaro/Zepbound 1 (active substance tirzepatide) from Eli Lilly the latter being the first dual receptor agonist 2 drug approved
A study published in the Cornell SC Johnson College of Business Research Paper Series found that in homes where at least one person was using the weight-loss medication, spending on groceries dropped 5.5% within six months, driven by fewer purchases of calorie-dense, processed foods
Body fat acts as insulation, helping the body retain heat
Start at the lower end of recommended ranges and assess your response over 2 to 4 weeks
Ozempic and Wegovy are brand names for the same active ingredient, Semaglutide
APP, amyloid precursor protein